WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2007002543) ANTIBODY FORMULATIONS HAVING OPTIMIZED AGGREGATION AND FRAGMENTATION PROFILES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2007/002543    International Application No.:    PCT/US2006/024717
Publication Date: 04.01.2007 International Filing Date: 23.06.2006
IPC:
C07K 16/10 (2006.01)
Applicants: MEDIMMUNE, INC. [US/US]; One MedImmune Way, Gaithersburg, MD 20878 (US) (For All Designated States Except US).
WEI, Ziping [US/US]; (US) (For US Only).
TOUS, Guillermo, I. [US/US]; (US) (For US Only).
SCHENERMAN, Mark [US/US]; (US) (For US Only).
ALLAN, Christian, B. [US/US]; (US) (For US Only)
Inventors: WEI, Ziping; (US).
TOUS, Guillermo, I.; (US).
SCHENERMAN, Mark; (US).
ALLAN, Christian, B.; (US)
Agent: MARTINEAU, Janet; MEDIMMUNE, INC., One Medimmune Way, Gaithersburg, Maryland 20878 (US)
Priority Data:
60/693,603 23.06.2005 US
60/699,614 15.07.2005 US
Title (EN) ANTIBODY FORMULATIONS HAVING OPTIMIZED AGGREGATION AND FRAGMENTATION PROFILES
(FR) FORMULATIONS D'ANTICORPS POSSEDANT DES PROFILS D'AGREGATION ET DE FRAGMENTATION OPTIMISES
Abstract: front page image
(EN)The present invention provides methods of optimizing the production and purification of antibody formulations that immunospecifically bind to antigens of interest and are suitable for parenteral administration to a subject, which formulations exhibit increased stability due to reduced degradation and aggregation of the antibody component on long term storage. Such methods provide formulations that offer multiple advantages over formulations produced by non-optimized methods including less stringent or more readily available transportation/storage conditions, and less frequent dosing or smaller dosage amounts in the therapeutic, prophylactic and diagnostic use of such formulations. The invention further provides methods of utilizing the formulations of the present invention.
(FR)L'invention concerne des procédés d'optimisation de la production et de la purification de formulation d'anticorps qui se lient de façon immunospécifique à des antigènes d'intérêt et qui conviennent à l'administration parentérale d'un sujet, ces formulations présentant une stabilité accrue du fait de la dégradation et de l'agrégation réduite du composant d'anticorps lors du stockage à long terme. Ces procédés fournissent des formulations qui offrent des avantages multiples sur des formulations produites par des procédés non optimisés possédant des conditions de stockage/transport disponibles plus rapidement ou moins stricts, et des dosages moins fréquents ou des quantités de dosage inférieures dans l'usage thérapeutique, prophylactique et diagnostique de ces formulations. L'invention concerne enfin des procédés d'utilisation de ces formulations.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)